GT200000086A - Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. - Google Patents
Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas.Info
- Publication number
- GT200000086A GT200000086A GT200000086A GT200000086A GT200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A
- Authority
- GT
- Guatemala
- Prior art keywords
- polymorphes
- citrate
- azobiciclo
- illamine
- oct
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCION SE REFIERE AL COMPUESTO DE FORMULA I, AL CITRATO MONOHIDRATO Y A SUS DOS POLIMORFOS A Y B, DADO QUE AMBOS POSEEN PROPIEDADES VALIOSAS, POR EJEMPLO LA ESTABILIDAD HIGROSCOPICA LO CUAL FAVORECE EL ENCAPSULAMIENTO; LA COMPOSICION FARMACEUTICA QUE CONTIENE AL MENOS UNO DE ESTOS POLIMORFOS TIENE UNA ESTABILIDAD VENTAJOSA PARA PACIENTES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES CONVENCIONALMENTE ORAL, MEDIANTE PREFERIBLEMENTE COMPRIMIDOS O CAPSULAS, E INTRAVENOSA. SE DESCRIBE TAMBIEN UN PROCEDIMIENTO DE OBTENCION DE LAS FORMAS A Y B. LA SAL CITRATO ES UN ANTAGONISTA DEL RECEPTOR NK1 ACTIVO DEL SISTEMA NERVIOSO CENTRAL Y ESTA INVENCION SE REFIERE A PROCEDIMIENTOS DE TRATAMIENTO DE AFECCIONES CAUSADAS O FAVORECIDAS POR UNA DISMINUCION DE LA NEUROTRANSMISION MEDIADA POR LA SUSTANCIA P. ESTA INVENCION SE REFIERE TAMBIEN A UN ANTAGONISTA DE LA SUSTANCIA P, EN EL QUE SE EVALUA LA EFICACIA ANTIEMETICA AGUDA Y RETARDADA EN UN MAMIFERO, INCLUYENDO HUMANOS, QUE RECIBE QUIMIOTERAPIA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13699599P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000086A true GT200000086A (es) | 2001-11-21 |
Family
ID=22475353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000086A GT200000086A (es) | 1999-06-01 | 2000-05-30 | Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6387925B1 (es) |
| EP (1) | EP1181289A1 (es) |
| JP (1) | JP2003501353A (es) |
| KR (1) | KR20020005055A (es) |
| CN (1) | CN1353712A (es) |
| AP (1) | AP2001002350A0 (es) |
| AR (1) | AR029753A1 (es) |
| AU (1) | AU767331B2 (es) |
| BG (1) | BG106139A (es) |
| BR (1) | BR0011125A (es) |
| CA (1) | CA2372236A1 (es) |
| CO (1) | CO5170468A1 (es) |
| CR (1) | CR6513A (es) |
| CZ (1) | CZ20014270A3 (es) |
| DZ (1) | DZ3051A1 (es) |
| EA (1) | EA004206B1 (es) |
| EE (1) | EE200100655A (es) |
| GT (1) | GT200000086A (es) |
| HK (1) | HK1046407A1 (es) |
| HN (1) | HN2000000076A (es) |
| HR (1) | HRP20010884A2 (es) |
| HU (1) | HUP0201798A3 (es) |
| IL (1) | IL145952A0 (es) |
| IS (1) | IS6129A (es) |
| MX (1) | MXPA01012328A (es) |
| NO (1) | NO20015845L (es) |
| NZ (1) | NZ514762A (es) |
| OA (1) | OA11955A (es) |
| PA (1) | PA8496001A1 (es) |
| PE (1) | PE20010155A1 (es) |
| PL (1) | PL352715A1 (es) |
| SK (1) | SK17342001A3 (es) |
| SV (1) | SV2002000092A (es) |
| TN (1) | TNSN00119A1 (es) |
| TR (1) | TR200103472T2 (es) |
| UY (1) | UY26177A1 (es) |
| WO (1) | WO2000073303A1 (es) |
| ZA (1) | ZA200109839B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031191A1 (en) * | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Azabicyclic spiroether derivatives as receptor antagonists |
| CA2529820A1 (en) * | 2003-06-18 | 2004-12-29 | Teva Pharmaceutical Industries Ltd | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them |
| US7371906B2 (en) | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| JPH0733386B2 (ja) * | 1991-05-31 | 1995-04-12 | フアイザー・インコーポレイテツド | キヌクリジン誘導体 |
| AU676489B2 (en) * | 1992-11-12 | 1997-03-13 | Pfizer Inc. | Quinuclidine derivative as substance P antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
-
2000
- 2000-05-12 US US09/887,682 patent/US6387925B1/en not_active Expired - Fee Related
- 2000-05-17 AP APAP/P/2001/002350A patent/AP2001002350A0/en unknown
- 2000-05-17 HR HR20010884A patent/HRP20010884A2/hr not_active Application Discontinuation
- 2000-05-17 EP EP00925526A patent/EP1181289A1/en not_active Withdrawn
- 2000-05-17 BR BR0011125-2A patent/BR0011125A/pt not_active IP Right Cessation
- 2000-05-17 SK SK1734-2001A patent/SK17342001A3/sk unknown
- 2000-05-17 EA EA200100982A patent/EA004206B1/ru not_active IP Right Cessation
- 2000-05-17 CA CA002372236A patent/CA2372236A1/en not_active Abandoned
- 2000-05-17 AU AU44246/00A patent/AU767331B2/en not_active Ceased
- 2000-05-17 NZ NZ514762A patent/NZ514762A/xx unknown
- 2000-05-17 HK HK02107840.5A patent/HK1046407A1/zh unknown
- 2000-05-17 IL IL14595200A patent/IL145952A0/xx unknown
- 2000-05-17 TR TR2001/03472T patent/TR200103472T2/xx unknown
- 2000-05-17 EE EEP200100655A patent/EE200100655A/xx unknown
- 2000-05-17 MX MXPA01012328A patent/MXPA01012328A/es not_active Application Discontinuation
- 2000-05-17 CZ CZ20014270A patent/CZ20014270A3/cs unknown
- 2000-05-17 JP JP2001500628A patent/JP2003501353A/ja active Pending
- 2000-05-17 HN HN2000000076A patent/HN2000000076A/es unknown
- 2000-05-17 KR KR1020017015324A patent/KR20020005055A/ko not_active Ceased
- 2000-05-17 OA OA1200100317A patent/OA11955A/en unknown
- 2000-05-17 CN CN00808340A patent/CN1353712A/zh active Pending
- 2000-05-17 WO PCT/IB2000/000663 patent/WO2000073303A1/en not_active Ceased
- 2000-05-17 PL PL00352715A patent/PL352715A1/xx not_active Application Discontinuation
- 2000-05-17 HU HU0201798A patent/HUP0201798A3/hu unknown
- 2000-05-19 PA PA20008496001A patent/PA8496001A1/es unknown
- 2000-05-26 CO CO00039192A patent/CO5170468A1/es not_active Application Discontinuation
- 2000-05-29 UY UY26177A patent/UY26177A1/es not_active Application Discontinuation
- 2000-05-30 PE PE2000000517A patent/PE20010155A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102664A patent/AR029753A1/es unknown
- 2000-05-30 GT GT200000086A patent/GT200000086A/es unknown
- 2000-05-31 DZ DZ000102A patent/DZ3051A1/xx active
- 2000-05-31 SV SV2000000092A patent/SV2002000092A/es unknown
- 2000-05-31 TN TNTNSN00119A patent/TNSN00119A1/fr unknown
-
2001
- 2001-10-26 IS IS6129A patent/IS6129A/is unknown
- 2001-11-23 BG BG106139A patent/BG106139A/bg unknown
- 2001-11-27 CR CR6513A patent/CR6513A/es not_active Application Discontinuation
- 2001-11-29 ZA ZA200109839A patent/ZA200109839B/xx unknown
- 2001-11-30 NO NO20015845A patent/NO20015845L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28496A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| NZ504986A (en) | Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| MA30221B1 (fr) | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| NO20043367L (no) | Oralt farmasoytisk preparat | |
| MA31706B1 (fr) | Formulations galéniques de composés organiques | |
| DK1377586T3 (da) | Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| SV1999000194A (es) | Preparado farmaceuticio de moxifloxacina ref. lea 33327-sv | |
| IL147852A0 (en) | Chemokine receptor antagonists and pharmaceutical compositions containing the same | |
| BG104640A (en) | Novel erythromycin derivatives | |
| EA200100416A1 (ru) | 13-членные азалиды и их применение в качестве антибиотических агентов | |
| AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| MA32275B1 (fr) | Preparations orales et injectables de composes de tetracycline | |
| EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| EA200500882A1 (ru) | N-арилсульфонил-3-аминоалкоксииндолы | |
| GT200000086A (es) | Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. | |
| CL2004000765A1 (es) | Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo. |